Literature DB >> 23664992

Characterization of the carbohydrate binding and ADP-ribosyltransferase activities of chemically detoxified pertussis toxins.

Hokyung Oh1, Byoung-Guk Kim, Kyung-Tak Nam, Seung-Hwa Hong, Dong-Ho Ahn, Gi-Sub Choi, Hyungjin Kim, Jin-Tae Hong, Byung-Yoon Ahn.   

Abstract

Pertussis toxin (PTx) is an essential component of the acellular pertussis (aP) vaccine. However, because PTx in its native form is considered too toxic for human vaccine use, it must be inactivated into a stable, nontoxic form by treatment with chemical detoxifying agents or by genetic modification. Therefore, testing for the residual PTx in the aP vaccine is a major quality control step for vaccine manufacturers and regulatory authorities. The histamine sensitization test is currently the standard safety test method for all aP vaccines, regardless of the vaccine formula or the detoxification process, except for those with genetically modified PTx. However, test result variability and ethical concerns regarding animal use necessitate an alternative method. In vitro assays based on the biochemical properties of PTx have been considered as potential alternatives to the histamine sensitization test. In this study, the suitability of assays based on the ADP-ribosyltransferase and carbohydrate binding activities of PTx was assessed for PTx after treatment with formaldehyde, glutaraldehyde or both denaturants in sequence. The results indicated a distinctive pattern of the biochemical activities depending on the detoxification methods and storage conditions. These results suggest that although a more careful study is needed, these in vitro biochemical assays can be considered potential alternatives to the histamine sensitization test, as they might provide more specific safety information of aP vaccines.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23664992     DOI: 10.1016/j.vaccine.2013.04.060

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Differences in epitope-specific antibodies to pertussis toxin after infection and acellular vaccinations.

Authors:  Aapo Knuutila; Tine Dalby; Alex-Mikael Barkoff; Charlotte Sværke Jørgensen; Kurt Fuursted; Jussi Mertsola; Kevin Markey; Qiushui He
Journal:  Clin Transl Immunology       Date:  2020-08-02

2.  Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.

Authors:  Carolina Salcedo-Rivillas; Anne-Sophie Debrie; Eliane Namie Miyaji; Jorge M C Ferreira; Isaías Raw; Camille Locht; Paulo L Ho; Nathalie Mielcarek; Maria Leonor S Oliveira
Journal:  Clin Vaccine Immunol       Date:  2014-05-07

3.  Alternatives to HIST for acellular pertussis vaccines: progress and challenges in replacement.

Authors:  J Arciniega; L Wagner; R Prymula; P Sebo; R Isbrucker; B Descampe; J M Chapsal; A Costanzo; C Hendriksen; M Hoonaker; S Nelson; K Lidster; W Casey; D Allen
Journal:  Pharmeur Bio Sci Notes       Date:  2016

Review 4.  Assays for Determining Pertussis Toxin Activity in Acellular Pertussis Vaccines.

Authors:  Kevin Markey; Catpagavalli Asokanathan; Ian Feavers
Journal:  Toxins (Basel)       Date:  2019-07-17       Impact factor: 4.546

Review 5.  Evaluation of Anti-PT Antibody Response after Pertussis Vaccination and Infection: The Importance of Both Quantity and Quality.

Authors:  Alex-Mikael Barkoff; Aapo Knuutila; Jussi Mertsola; Qiushui He
Journal:  Toxins (Basel)       Date:  2021-07-21       Impact factor: 4.546

Review 6.  In Vivo Models and In Vitro Assays for the Assessment of Pertussis Toxin Activity.

Authors:  Marieke Esther Hoonakker
Journal:  Toxins (Basel)       Date:  2021-08-12       Impact factor: 4.546

7.  Safety testing of acellular pertussis vaccines: Use of animals and 3Rs alternatives.

Authors:  Marieke Hoonakker; Juan Arciniega; Coenraad Hendriksen
Journal:  Hum Vaccin Immunother       Date:  2017-11-02       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.